Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Inclusion Criteria:

Dose Escalation:

- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
who have received standard of care therapy or are ineligible to receive such
therapy.

Phase II:

- Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell
lung cancer who have received platinum-based chemotherapy regimen and immune
checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy

- Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal
cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy, unless patient was ineligible to such therapy.

All patients:

- ECOG performance status of 0 or 1.

- Patients must have a site of disease amenable to biopsy and be a candidate for tumor
biopsy according to the treating institution's guidelines.

Exclusion Criteria:

- Tumors harboring driver mutations that have approved targeted therapies, with the
exception of KRAS G12C mutations

- Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of
groups in Phase II.

- Active brain metastases, including symptomatic brain metastases or known
leptomeningeal disease

- Clinically significant cardiac disease or risk factors at screening

- Insufficient bone marrow, hepatic or renal function at screening Other
protocol-defined inclusion/exclusion criteria may apply